UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/085,239	02/27/2002	Simon Ward	674569-2001	1714
	7590 06/25/200 AWRENCE & HAUG		EXAMINER	
745 FIFTH AV	ENUE- 10TH FL.		ROYDS, LESLIE A	
NEW YORK, N	NY 10151		ART UNIT	PAPER NUMBER
			1614	
			MAIL DATE	DELIVERY MODE
			06/25/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/085,239	WARD ET AL.	
Examiner	Art Unit	
Leslie A. Royds	1614	

	Leslie A. Royds	1614				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress			
THE REPLY FILED 11 June 2008 FAILS TO PLACE THIS APP	LICATION IN CONDITION FOR A	LLOWANCE.				
1.  The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following rapplication in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:	replies: (1) an amendment, affidaviral (with appeal fee) in compliance	t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request			
a) The period for reply expires <u>5</u> months from the mailing date b) The period for reply expires on: (1) the mailing date of this Adno event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (I MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	dvisory Action, or (2) the date set forth tter than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	g date of the final rejectio	n.			
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extrunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the siset forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount of hortened statutory period for reply origi	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as			
2. The Notice of Appeal was filed on A brief in compl filing the Notice of Appeal (37 CFR 41.37(a)), or any exten Notice of Appeal has been filed, any reply must be filed with AMENDMENTS	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the				
3. ☐ The proposed amendment(s) filed after a final rejection, b  (a) ☐ They raise new issues that would require further con  (b) ☐ They raise the issue of new matter (see NOTE below  (c) ☐ They are not deemed to place the application in bett appeal; and/or  (d) ☐ They present additional claims without canceling a content of the second	nsideration and/or search (see NOTw); ver form for appeal by materially reconstructions or repeated by materially rejectors.	TE below);				
NOTE: See Continuation Sheet. (See 37 CFR 1.124. The amendments are not in compliance with 37 CFR 1.125. Applicant's reply has overcome the following rejection(s):  Newly proposed or amended claim(s) would be allowed an endowable claim(s).  To purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proven the second structure.	21. See attached Notice of Non-Col  bowable if submitted in a separate, t  will not be entered, or b)   will	imely filed amendmen	nt canceling the			
The status of the claim(s) is (or will be) as follows:  Claim(s) allowed:  Claim(s) objected to: 43,48 and 51.  Claim(s) rejected: 40-42 and 44-50.  Claim(s) withdrawn from consideration:  AFFIDAVIT OR OTHER EVIDENCE						
<ol> <li>The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>						
9. The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	al and/or appellant fails	s to provide a			
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER		•				
11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:  See Continuation Sheet.						
<ul><li>12. ☐ Note the attached Information <i>Disclosure Statement</i>(s). (</li><li>13. ☐ Other:</li></ul>	PTO/SB/08) Paper No(s)					
/Ardin Marschel/ Supervisory Patent Examiner, Art Unit 1614	/Leslie A. Royds/ Patent Examiner, Art Un	it 1614				

Continuation of 3. NOTE:

Applicant's proposed after-final amendment filed June 11, 2008 will not be entered into the record because the proposed amendments to claims 40-42, 44-46 and 48-50 raise new issues that require further consideration and/or search.

Firstly, Applicant proposes amending present claims 40-42 to change the transitional language of the claims from "consisting essentially of" to "consisting", proposes amending present claims 44-46 from "comprising" to "by" and limiting the composition to "consisting of" and further proposes amending present claims 48-50 to change the transitional language from "comprising" to "consisting of". This proposed amendment narrows the scope of the claimed subject matter to only those components specifically recited by the claims. In other words, further consideration of the presently applied art under 35 U.S.C. 103(a) would be required, as well as an additional assessment of the prior art to determine whether such an amendment would obviate the art of record and/or whether additional art would need to be applied.

Secondly, Applicant has also added a new limitation to present claims 40-42, 44-46 and 48-50 directed to the use of one or more pharmaceutically acceptable carriers, diluents or excipients in the claimed pharmaceutical composition. This newly added limitation has neither been previously searched nor considered, and, therefore, clearly raises a new issue that requires further consideration and/or search.

Accordingly, the proposed claim amendments are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal because they raise new issues that require further consideration and/or search.

Continuation of 11. does NOT place the application in condition for allowance because:

Applicant's request for reconsideration of the present application with regard to the present objections and rejections under 35 U.S.C. 112, second paragraph, and 35 U.S.C. 103(a) in light of the amendments to the claims proposed and presented in the after-final amendment has been made. In light of the fact that the proposed amendments to the claims will not be entered into the record, Applicant's remarks directed to the obviation of these objections and rejections as a result of the proposed amendments are not found persuasive.

Accordingly, in the absence of any additional arguments or remarks regarding the patentability of the instant claims pending at the time of the final rejection, the Examiner defers to the reasons already set forth in the final rejection dated January 11, 2008. In view of the fact that the proposed after-final amendments will not be entered for the reasons explained supra, the claims remain objected to or rejected for the reasons of record previously set forth in the final rejection of January 11, 2008, of which said reasons are herein incorporated by reference.

/Leslie A. Royds/ Patent Examiner, Art Unit 1614